Sibylle Junge

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

Félix Ratjen, Christopher Hug, Gautham Marigowda et al. · The Lancet Respiratory Medicine · 2017 · 291 citations

Pulmonary Fibrosis, Medicine, Placebo-controlled Phase 3

Quality of life is associated with physical activity and fitness in cystic fibrosis

Helge Hebestreit, Kerstin Schmid, Stephanie Kieser et al. · BMC Pulmonary Medicine · 2014 · 145 citations · Full text

Cardiopulmonary Exercise Testing Provides Additional Prognostic Information in Cystic Fibrosis

Helge Hebestreit, Erik H.J. Hulzebos, Jane E. Schneiderman et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 139 citations · Full text

Long-term effects of a partially supervised conditioning programme in cystic fibrosis

Helge Hebestreit, Stephanie Kieser, Sibylle Junge et al. · European Respiratory Journal · 2009 · 136 citations · Full text

Physical activity is independently related to aerobic capacity in cystic fibrosis

Helge Hebestreit, Stephanie Kieser, Stefan G. Rüdiger et al. · European Respiratory Journal · 2006 · 136 citations · Full text

Physical Activity, Kinesiology, Exercise +15